2019 Program

Fireside Chat Series – The Purposeful CEO: Fulfilling the promise through company transformation

Summit Overview & Rules of Engagement

The Pulse of European Biotech: Building momentum?

A top line interactive dialogue on the state of Europe’s biotech industry, where it stands today, how it is impacting companies and its future prospects.

Biotech Perspectives: Competition at a crossroads

For leaders in the biotech industry, every success seems to bring on a new set of challenges.  The Summit participants will receive case study background on a previously sleepy area of therapeutic development that is now becoming a hotbed of competition.  The participants will be organized in teams and given their case study before the break. After the break, the teams meet to discuss their case study and develop recommendations for the CEO.

Biotech Perspectives: What should the CEO do?  (Breakout team discussions)

Instructions: Biotech leaders may have one of the most difficult general management roles in industry. They often reach the executive suite through a particular functional expertise (research, finance, commercial). Soon, however, they face challenges that require an integrated understanding of multiple disciplines. Each team will discuss a situation where a CEO must lead in an area that is outside of his/her comfort zone. The participants will be asked to develop recommendations for the CEO of their case study.

Teams Reconvene: Each team will present the specific challenges the CEO of their company faced and their recommendations for handling the situation.

BD Strategy: Making sense of your options – The path to a decision

When pursuing a partner, all opportunities and options have costs. How do you determine the options to pursue that lead to the best chance of success for your company?

Spotlight: The pharma perspective

Finance: Feeding your company the capital it needs to get beyond the starvation diet

How does a European CEO raise the capital it needs to move its company forward? Is it necessary in this environment to tap into the US market?

Market Access – It’s always too early, until it’s too late – thinking globally & staying ahead of the game

Market access has been a critical, and increasingly complex, issue in the industry for almost 20 years now, yet many leave planning to the last minute. Reimbursement is the key to operating cash flow for a medicine, a more accurate valuation and better alignment in business development discussions, yet many companies leave planning until after regulatory and clinical programs are finalized. Better and earlier access planning creates a better understanding of evidence and data needs for both payers and capital needs, more accurate net pricing estimates, and ultimately, a more realistic valuation model with fewer downside surprises.

Business and Boards: Forming a trusted relationship to support the success of the company

Leading a company can be a turbulent ride in the biotech industry. How does a CEO get the board he/she needs?

Building a Team Smartly: The essentials for success

The team surrounding a CEO is critical to the success of the company. How do you assess the strengths of your team to understand its weaknesses to identify your needs?

CEO Spotlight: From CEO of a major public company to board member of private companies, the eye-opening view from both sides.

CEO Assessment: Results and discussion

A review of the annual CEO Summit and comparison to past years and the US assessments.

Communications: The critical role of building and maintaining your company’s reputation

Reputation building is particularly challenging for biotech companies due to their business model. This intangible asset however creates real value and therefore should be an objective for every company. A top line interactive discussion and experience exchange on the critical role of strategic communications in building and maintaining the reputation and brand of your company.

An Unguarded Conversation Among Friends

Questions will be solicited anonymously from attendees during the course of the Summit and presented for discussion.